BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25677770)

  • 1. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
    Naydenova E; Todorov P; Zamfirova R
    Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.
    Lohman RJ; Harrison RS; Ruiz-Gómez G; Hoang HN; Shepherd NE; Chow S; Hill TA; Madala PK; Fairlie DP
    Vitam Horm; 2015; 97():1-55. PubMed ID: 25677767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nociceptin, endogenous opioid peptide. Preface.
    Litwack G
    Vitam Horm; 2015; 97():xv-xvi. PubMed ID: 25677779
    [No Abstract]   [Full Text] [Related]  

  • 4. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.
    Zaveri N; Jiang F; Olsen C; Polgar W; Toll L
    AAPS J; 2005 Oct; 7(2):E345-52. PubMed ID: 16353914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
    Wtorek K; Janecka A
    Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pain regulation by nocistatin-targeting molecules: G protein-coupled-receptor and nocistatin-interacting protein.
    Okuda-Ashitaka E; Ito S
    Vitam Horm; 2015; 97():147-65. PubMed ID: 25677771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
    Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
    Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.
    Bojnik E; Babos F; Fischetti C; Magyar A; Camarda V; Borsodi A; Bajusz S; Calo' G; Benyhe S
    Brain Res Bull; 2010 Mar; 81(4-5):477-83. PubMed ID: 19800951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
    Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
    J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
    Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
    Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
    J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
    Calo G; Guerrini R; Rizzi A; Salvadori S; Burmeister M; Kapusta DR; Lambert DG; Regoli D
    CNS Drug Rev; 2005; 11(2):97-112. PubMed ID: 16007234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.
    Calo' G; Rizzi A; Cifani C; Micioni Di Bonaventura MV; Regoli D; Massi M; Salvadori S; Lambert DG; Guerrini R
    CNS Neurosci Ther; 2011 Jun; 17(3):178-98. PubMed ID: 20497197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?
    Zeilhofer HU; Calò G
    J Pharmacol Exp Ther; 2003 Aug; 306(2):423-9. PubMed ID: 12721334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
    Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
    Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
    Zaveri NT
    Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
    Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
    J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOP-Targeted Nonpeptide Ligands.
    Zaveri NT; Meyer ME
    Handb Exp Pharmacol; 2019; 254():37-67. PubMed ID: 31119463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia.
    Scoto GM; Aricò G; Ronsisvalle S; Parenti C
    Peptides; 2007 Jul; 28(7):1441-6. PubMed ID: 17628212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.